louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05662774: Clinical Application of Quantitative Ultrasonographic Analysis in Early Kidney Injury
Official title: The Clinical Application of Ultrasound for Acute Kidney Injury During Sepsis - From Macroscopic to Microscopic Renal Perfusion Perspectives
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Patient Admitted to Hospital With Acute Kidney Injury Due to Sepsis
Keywords: Acute kidney injury
contrast-enhanced ultrasound
renal perfusion
microcirculation
Lead sponsor: Second Affiliated Hospital of Soochow University
Sponsor class: OTHER
First posted: 2022-12-22
Enrollment: 100
Sex: ALL
Minimum age (years): 19
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: All patients admitted to the Intensive Care Unit who meet the above inclusion criteria

Brief summary: The purpose of this study was to quantify overall blood flow and renal cortical perfusion in patients with septic acute kidney injury (AKI) using ultrasound (US) Doppler and contrast-enhanced ultrasound (CEUS).

Detailed description: Kidney ultrasound is the most widely used imaging modality in initial AKI workup as it is widely available and free of complications. It is clinically feasible to use US Doppler and contrast-enhanced US (CEUS) to detect macroscopic and microscopic changes in renal blood flow, and also cardiac output alterations.The aim was to analyze changes in US Doppler and CEUS quantitative parameters in patients with septic AKI to explore perfusion within the renal parenchyma, and also measure global renal blood flow and cardiac output.

Eligibility criteria: Inclusion Criteria:

1. Meets the AKI diagnostic criteria of the Kidney Disease: Improving Global Outcomes (KDIGO)
2. Meets Sepsis 3.0 diagnostic criteria for sepsis: infection + SOFA ≥ 2

Exclusion Criteria:

1. Urinary tract obstruction, hydronephrosis, etc.
2. Left ventricular ejection fraction \<30% (measured by transthoracic echocardiography), systolic pulmonary artery pressure \>90 mmHg (measured by transthoracic echocardiography)
3. Allergy or adverse reaction to contrast media

Primary outcomes:
measure: Ultrasound Doppler parameters
timeFrame: First 24 hours after admission
measure: Ultrasound Doppler parameters
timeFrame: First 24 hours after admission
measure: Ultrasonography parameters
timeFrame: First 24 hours after admission
measure: Ultrasonography parameters
timeFrame: First 24 hours after admission
measure: Ultrasonography parameters
timeFrame: First 24 hours after admission
Secondary outcomes:
Other outcomes:
Locations:
city: Suzhou
country: China
facility: The Second Hospital of Soochow University
state: Jiangsu
Study officials:
affiliation: The Second Hospital of Soochow University
name: The Second Hospital of Soochow University The Second Hospital of Soochow University
role: STUDY_CHAIR
References:
Clinical trial NCT00237874: Aripiprazole Treatment of Prodromal Patients
Official title: Aripiprazole Treatment of Prodromal Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Schizophrenia
Psychosis
Keywords: prodrome
ultra high risk
aripiprazole
Lead sponsor: Yale University
Sponsor class: OTHER
Collaborators: name: Bristol-Myers Squibb
First posted: 2005-10-12
Enrollment: 15
Sex: ALL
Minimum age (years): 13
Maximum age (years): 40
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: We hypothesize that symptoms will improve in patients who meet diagnostic criteria for the schizophrenia prodrome when they are prescribed aripiprazole.

Detailed description: This is an 8 week trial with extension for responders out to one year. All patients receive active medication; there is no placebo. Patients must meet criteria for the schizophrenia prodrome according to the Structured Interview for Prodromal Syndromes. Patients receive counseling as well. All counseling and medication are free of charge.

Eligibility criteria: Inclusion Criteria:

* age 13 to 40 meet criteria for the prodrome for schizophrenia

Exclusion Criteria:

* history of psychosis

Primary outcomes:
measure: Total Score of the Scale Of Prodromal Symptoms
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Hartford
country: United States
facility: Institute of Living
state: Connecticut
city: New Haven
country: United States
facility: Yale School of Medicine
state: Connecticut
Study officials:
affiliation: Yale University
name: Scott W Woods, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02406274: Use of Contrast Enhanced Spectral Mammography (CESM) for Women With Palpable Breast Abnormalities
Official title: Use of Contrast Enhanced Spectral Mammography (CESM) for Women With Palpable Breast Abnormalities
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Abnormalities
Keywords: Mammography
Contrast Enhanced Spectral Mammography
Palpable Breast Abnormalities
15-053
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2015-04-02
Enrollment: 249
Sex: FEMALE
Minimum age (years): 25
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Contrast Enhanced Spectral Mammography (CESM) is an advanced form of mammography which is performed after injection of contrast or dye into a vein in the arm. This dye is the same dye that is used for CT scans. This type of mammogram includes a regular mammogram as well as additional pictures with the dye.

This particular study is being done to determine if by adding the dye in the veins the investigators are better able to identify the cause of the lump than if they just did the regular mammogram alone.


Eligibility criteria: Inclusion Criteria:

* Women presenting for mammographic evaluation of an undiagnosed palpable mass found either by self examination and/or examination by referring physician

Exclusion Criteria:

* Age \< 25 years old
* Male patients
* Pregnant or lactating patients
* Patients with allergy to iodinated contrast
* Patients with a history of renal disease or patients over 70 with a creatinine \> 1.3. Creatinine must have been done within the last 12 weeks.

Primary outcomes:
measure: positive predictive value
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Maxine Jochelson, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00581074: Effects of Grapefruit or Grapefruit Juice on Anthropometry, Dietary Intakes, Appetite, and Metabolic Profile in Overweight and Obese Young and Middle-Aged Adults
Official title: Effects of Grapefruit or Grapefruit Juice on Anthropometry, Dietary Intakes, Appetite, and Metabolic Profile in Overweight and Obese Young and Middle-Aged Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Keywords: obesity
diet
weight loss
metabolic syndrome
Lead sponsor: Vanderbilt University
Sponsor class: OTHER
First posted: 2007-12-27
Enrollment: 90
Sex: ALL
Minimum age (years): 21
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This trial examines the effects of grapefruit or grapefruit juice on anthropometry, dietary intakes, appetite, and metabolic profile in overweight and obese young and middle-aged adults.


Eligibility criteria: Inclusion Criteria:

* BMI 30-39.9

Exclusion Criteria:

* Pregnant or lactating
* On medications that are interfered with by consuming grapefruit juice

Primary outcomes:
measure: weight loss
timeFrame: 3 months
Secondary outcomes:
measure: metabolic syndrome
timeFrame: 3 months
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Vanderbilt University
state: Tennessee
Study officials:
affiliation: Vanderbilt University
name: Heidi J Silver, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Silver HJ, Dietrich MS, Niswender KD. Effects of grapefruit, grapefruit juice and water preloads on energy balance, weight loss, body composition, and cardiometabolic risk in free-living obese adults. Nutr Metab (Lond). 2011 Feb 2;8(1):8. doi: 10.1186/1743-7075-8-8.
Clinical trial NCT03806374: Is it Possible to Replace Fentanyl in Anesthesia for Minor Procedures?
Official title: Is it Possible to Replace Fentanyl by Non Narcotic Medication for Induction and Maintenance of Anesthesia in Minor Procedures?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anesthesia
Keywords: fentanyl
lidocaine
ketamine
induction of anesthesia
intubation
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2019-01-16
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: To compare between fentanyl group and ketamine lidocaine group for induction of anesthesia as regards hemodynamics and smooth intubation.

Detailed description: Two groups each with 60 patients Group I anesthesia initiated by propofol, fentanyl and cisatracurium. Group II anesthesia initiated by ketamine, lidocaine, propofol and cisatracurium.

Eligibility criteria: Inclusion Criteria:

* ASA I and II between
* Age between 18-55 years
* Undergoing minor surgical procedure less than an hour.

Exclusion Criteria:

* Patients with hypertension
* Patients with Ischemic heart diseases
* Patients with chronic renal or liver diseases

Primary outcomes:
measure: Intubation with less hemodynamic changes
timeFrame: 15 minutes after induction of anesthesia.
measure: Smooth Maintenance of anesthesia
timeFrame: anesthesia time
measure: less postoperative pain killers
timeFrame: 24 hours postoperative
measure: Intubation with less hemodynamic changes
timeFrame: Anesthesia time
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain Shams University hospitals
Study officials:
References:
Clinical trial NCT02137174: Home and School Visits Intervention for Children With DM TYPE 1
Official title: The Efficacy of Constructed Intervention by Home and School Visits on Glycemic Control in Children With Type I Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Diabetes Type 1
Lead sponsor: Ben-Gurion University of the Negev
Sponsor class: OTHER
First posted: 2014-05-13
Enrollment: 92
Sex: ALL
Minimum age (years): 4
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Home and school visits by multidisciplinary team will improve metabolic control in kids having insulin dependent diabetes mellitus


Eligibility criteria: Inclusion Criteria:

* HbA1c ≥ 8% at baseline, and diabetes duration of at least 7 months.

Exclusion Criteria:

* Patients during honeymoon period
* Patients and their parents who do not speak Hebrew or Arabic
* Patients who were not under any educational system
* Patients who had other severe chronic disorders

Primary outcomes:
measure: HBA1C
timeFrame: 2 YEARS
Secondary outcomes:
measure: Number of DKA episodes
timeFrame: 2 YEARS
measure: Number of Hospitalizations
timeFrame: 2 years
measure: Hypoglycemia rate
timeFrame: 2 years
Other outcomes:
Locations:
city: Beer Sheva
country: Israel
facility: Pediatric Endocrinology Unit, Soroka Medical Center
Study officials:
References:
Clinical trial NCT05166174: Lower Uterine Segment Following a Cesarean Section With Barbed Suture
Official title: Lower Uterine Segment at the Next Pregnancy Following a Cesarean Section With Barbed Suture: an Observational Prospective Comparative Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cesarean Wound; Dehiscence
Cesarean Section Complications
Keywords: barbed suture
uterine lower segment
cesarean section
Lead sponsor: Piazza della Vittoria 14 Studio Medico - Ginecologia e Ostetricia
Sponsor class: OTHER
First posted: 2021-12-21
Enrollment: 93
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pregnant women who underwent a previous elective cesarean section at term of pregnancy, during which the anteriore uterine wall was closed by using barbed or conventional smooth suture

Brief summary: This aim of this study is to investigate the LUS in the pregnancy following a previous cesarean section with the use of barbed or conventional smooth suture.

Detailed description: To better assess the risk of uterine rupture, some authors have proposed sonographic measurement of lower uterine segment (LUS) thickness near term, assuming that there is an inverse correlation between LUS thickness and the risk of uterine scar defect. Recently, barbed suture has been employed for closing uterine wall after cesarean section, demonstrating the reduction of closure time of the uterine incision and estimated blood loss. Until now, the impact of barbed suture in future pregnancies has not been investigated.

Eligibility criteria: Inclusion Criteria:

* pregnant women
* being undergone a previous elective cesarean section at term of pregnancy (more than 37 weeks of gestation), in which barbed or conventional smooth suture was used for closing anterior uterine wall

Exclusion Criteria:

* having done more than one cesarean section
* having done a previous urgent cesarean section
* having done previous uterine surgical procedures with exception than one cesarean section

Primary outcomes:
measure: Ultrasonographic measure of lower uterine segment thickness
timeFrame: 34-38 weeks following study enrollment
Secondary outcomes:
Other outcomes:
Locations:
city: Genoa
country: Italy
facility: Piazza della Vittoria 14
Study officials:
affiliation: Piazza della Vittoria 14, Genoa, Italy
name: Simone Ferrero
role: PRINCIPAL_INVESTIGATOR
References:
citation: Jastrow N, Chaillet N, Roberge S, Morency AM, Lacasse Y, Bujold E. Sonographic lower uterine segment thickness and risk of uterine scar defect: a systematic review. J Obstet Gynaecol Can. 2010 Apr;32(4):321-327. doi: 10.1016/S1701-2163(16)34475-9.
citation: Alessandri F, Evangelisti G, Centurioni MG, Gustavino C, Ferrero S, Barra F. Fishbone double-layer barbed suture in cesarean section: a help in preventing long-term obstetric sequelae? Arch Gynecol Obstet. 2021 Sep;304(3):573-576. doi: 10.1007/s00404-021-06121-8.
Clinical trial NCT00701974: Non-inferiority Clinic of Kollagenase® Compared Iruxol® in Treatment of Cutaneous Ulcers
Official title: Study of Non Inferiority of Product Kollagenase ®, Manufactured by Laboratory Cristália When Compared With Iruxol ®, Manufactured by Abbott Laboratory, in the Treatment of Cutaneous Ulcers
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: PHASE2
PHASE3
Conditions: Ulcers
Keywords: Non-inferiority based on efficiency
Lead sponsor: Azidus Brasil
Sponsor class: INDUSTRY
First posted: 2008-06-19
Enrollment: 66
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Skin ulcers can be defined as open injuries, loss of substances with the skin or mucous tissue, caused by disintegration and tissue necrosis. Chronic skin ulcer is any injury that heal in a period not less than 6 weeks. Several etiological causes for the emergence of skin ulcers. Around 73% are venous, arterial are 8%, 3% are diabetic, 2% are traumatic and 14% are from other causes.

Clinical studies show that collagenase is an effective drug and presents high tolerabildade in the treatment of ulcerative burns and injuries of various etiologies. Evidence show statistically significant reduction of inflammation, the formation of granulation tissue, decrease in injuries and reepitelization.


Eligibility criteria: Inclusion Criteria:

* Patients of both sexes aged over 18 years
* people with skin ulcers of the lower limbs for at least 3 months

Exclusion Criteria:

* Lesion with a diameter larger than 12 cm ²
* injury over 2 years of evolution; injury infected
* neoplastic lesions in activity
* poorly controlled diabetes mellitus
* HAS poorly controlled
* signs of ischemia in the limb
* not offset any disease
* allergic to components of formula
* urticaria
* pregnancy
* breastfeeding
* emotional disturbance

Primary outcomes:
measure: Primary: Non-inferiority based on efficiency that will be evaluated by the general improvement of the injury; Secondary: tolerability assessed by the incidence of adverse events.
timeFrame: healing
Secondary outcomes:
Other outcomes:
Locations:
city: Valinhos
country: Brazil
facility: Lal Clinica
state: Sao Paulo
Study officials:
References:
Clinical trial NCT04674774: Efficacy of Tegoprazan Based Bismuth Quadruple Therapy for Helicobacter Pylori Infection
Official title: Efficacy of Tegoprazan Based Bismuth Quadruple Therapy Compared With Bismuth Quadruple Therapy for Helicobacter Pylori Infection: Randomized, Double-blind, Active-Controlled Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Helicobacter Pylori Infection
Lead sponsor: Incheon St.Mary's Hospital
Sponsor class: OTHER
First posted: 2020-12-19
Enrollment: 217
Sex: ALL
Minimum age (years): 19
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to investigate eradication rate, drug compliance, and adverse events in patients with confirmed Helicobacter pylori infection between tegoprazan, bismuth, metronidazole, and tetracycline for 14 days (TBMT) and PPI, bismuth, metronidazole, and tetracycline for 14 days (LBMT)

Detailed description: This is a multi-center, double-blind, randomized, active-controlled study.

Eligibility criteria: Inclusion Criteria:

patients who male or female aged 19 to 75 years old and fall under the following conditions with confirmed helicobacter pylori infection

Exclusion Criteria:

1. patients who have H.pylori eradication history
2. patients with history of gastric cancer surgery
3. patients who have taken antibiotics within 4 weeks prior to trial
4. a person who taking HIV protease inhibitors (atazanavir, nelfinavir) or a drug containing rilpivirine
5. pregnant or breastfeeding women

Primary outcomes:
measure: H. pylori eradication rate of each group
timeFrame: UBT test 4 weeks after completion of eradication treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Incheon
country: Korea, Republic of
facility: Incheon St. Mary's Hospital
Study officials:
References:
Clinical trial NCT00153374: Iowa WISEWOMAN Project
Official title: Iowa WISEWOMAN Project
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: CVD Risk
Lead sponsor: Centers for Disease Control and Prevention
Sponsor class: FED
First posted: 2005-09-12
Sex: FEMALE
Minimum age (years): 40
Maximum age (years): 64
Standard ages: ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: To provide low-income, under- or uninsured 40- to 64-year-old women with the knowledge, skills, and opportunities to improve diet, physical activity, and other lifestyle behaviors to prevent, delay and control cardiovascular and other chronic diseases.


Eligibility criteria: Inclusion Criteria:

* NBCCEDP

Exclusion Criteria:

-

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Centers for Disease Control and Prevention
name: Julie Will
role: STUDY_CHAIR
References:
Clinical trial NCT02407574: Assessment of the Force Frequency Relationship of the Myocardium After On-pump CABG Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Adult Cardiac Surgery
Lead sponsor: University of Liege
Sponsor class: OTHER
First posted: 2015-04-03
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The aim of the study is to determine whether increasing the heart rate by epicardial atrial pacing after surgery improves the contractile force of the myocardium. After complete weaning from CPB, several pressure-loops of the LV will be recorded at different levels of preload using transoesophageal echo, invasive blood pressure monitoring. The preload will be manipulated by adding fluid from the CPB reservoir or draining fluid into the CPB reservoir.


Eligibility criteria: Inclusion Criteria:

* CABG only surgery
* Preopeartive LVEF ≥ 53 %
* Use of epicardial pacing wires to assist CPB weaning

Exclusion Criteria:

* Contra-indication to TEE
* AV block at the time of CPB weaning
* Sinus rhythm less than 50 or more than 90 BPM after CPB weaning.

Primary outcomes:
measure: End-systolic elastane of the left ventricle.
timeFrame: 30 minutes after CPB weaning
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: